Meanwhile, in exudative AMD, combining anti-VEGF therapies like ranibizumab or aflibercept with angiopoietin-2 inhibitors (Vabysmo) offers a comprehensive approach to managing vascular leakage and neovascularization. The gene discussed is VEGFA; the disease is age-related macular degeneration.